Johnson & Johnson
Recent News About Johnson & Johnson
-
West Virginia isn't part of proposed $26 billion national opioid settlement
CHARLESTON – While a bipartisan group of state attorneys general have announced a tentative $26 billion settlement with four drug companies over their roles in the opioid epidemic, West Virginia will not be a part of the agreement. -
Johnson & Johnson claims FDA's new asbestos testing based on 'faulty assumptions'
WASHINGTON (Legal Newsline) - Johnson & Johnson says a Food and Drug Administration panel charged with designing new standards for detecting asbestos in talc used “faulty assumptions” and failed to reflect scientific consensus in its draft recommendations. -
Oklahoma wanted decades of funding from opioid verdict, but will get only one year's worth
NORMAN, Okla. (Legal Newsline) – Oklahoma’s landmark verdict in its opioid case against Johnson & Johnson does not mean the company must pump billions of dollars into the state over the next 30 years, a judge ruled Friday. -
'Wholly inadequate': Lawyers seek more opioid money by avoiding global settlement process
A proposed “negotiation class” to settle all opioid litigation by U.S. cities and counties could be in deep trouble, as the U.S. Court of Appeals for the Sixth Circuit considers an appeal of the order creating the controversial class and lawyers in two states with big claims urge their clients to opt out before a Nov. 22 deadline. -
'Absolute panic' as cities, counties face deadline on opioid 'negotiation class'
CLEVELAND (Legal Newsline) - Cities and counties are worried and confused as they face a November deadline to join or opt out of an unprecedented “negotiation class” that could determine how much money they get from opioid litigation, a lawyer who represents Texas municipalities said. -
Jurors won't get confused during huge opioid trial, judge rules; He'll set penalties after
CLEVELAND (Legal Newsline) – A jury will determine who, if anyone, is liable for the nation’s addiction crisis, but the judge overseeing a historic trial will decide how much they would pay. -
Oklahoma judge feeds the 'monster' with $572M opioid ruling against Johnson & Johnson
Sixteen years ago in a case involving gunmaker Sturm, Ruger & Co., a New York appeals court refused to apply public nuisance law against the manufacturer of a legal product, saying that doing so would transform nuisance law “into a monster that would devour in one gulp the entire law of tort.” -
Private lawyers stand to make $90 million as judge hits Johnson & Johnson with $572M opioid ruling
NORMAN, Okla. (Legal Newsline) - A state judge in Oklahoma has blamed Johnson & Johnson for the state's opioid crisis and ordered it to pay $572 million in damages, extending public nuisance law beyond its traditional boundaries into what may become an all-purpose tool for government lawsuits against product manufacturers. -
Opioid judge supports `negotiating class,’ tells critics like state AGs to `come up with a better model’
CLEVELAND (Legal Newsline) - The federal judge overseeing multidistrict litigation against opioid manufacturers and distributors left little doubt he supports a plan developed by private lawyers to assemble an unprecedented “negotiating class” consisting of every city and county in the U.S. -
Tensions run high in OK opioid trial Thursday; State focuses on risk data J&J relied on
NORMAN, Okla. (Legal Newsline) - Tensions ran high in court Thursday as the Oklahoma opioid trial continued, with defense attorney Larry Ottoway objecting throughout the day to opposing counsel's line of questioning directed at defense witness, business director for Janssen Pharmaceuticals Kimberly Deem-Eshleman. -
Father recounts loss of son in Oklahoma Johnson & Johnson opioid trial
NORMAN, Okla. (Legal Newsline) – Fighting back tears, a father who lost his son to an opioid overdose recounted the nightmare during testimony in a trial alleging that Johnson & Johnson flooded the state with addictive drugs for profit. -
Hunter: Case is about abating 'worst' man-made crisis; J&J: Case is about damages - not abatement
NORMAN, Okla. (Legal Newsline) - Admitting there is a high potential for abuse in opioid medications, Johnson & Johnson attorney Larry Ottaway said during opening arguments on Tuesday that physicians prescribing its medications Nucynta and Duragesic know this risk and have to know it to be licensed. -
Hospitals sue opioid manufacturers, distributors to recoup costs of opioid epidemic
MOUNDSVILLE — Thirty-seven hospitals in West Virginia and Kentucky are suing opioid manufacturers and distributors they claim caused the crisis in the area. -
Pelvic mesh lawyers pressured clients to dismiss cases to avoid costs of trial
CHARLESTON, W.Va. (Legal Newsline) - A law firm representing thousands of pelvic mesh plaintiffs gave some of its clients two days to decide whether to dismiss their lawsuits and accept a proffered settlement from Johnson & Johnson, or risk incurring substantial costs preparing for trial. -
Multidistrict litigation swamps courts as rules struggle to catch up; Is reform on the way?
Multidistrict litigation – sprawling cases sometimes involving thousands of plaintiffs from all over the country – now represents more than half of the civil caseload in federal courts, according to a new survey, yet defendants complain the rules governing them are largely judge-made and haphazardly enforced. -
Trial lawyers are paying millions to a handful of experts necessary to push their talc cases
A small group of highly paid experts, one of whom recently testified his firm has made $30 million offering mostly pro-plaintiff testimony, are the key ingredient for more than 10,000 lawsuits claiming talcum powder is laced with deadly asbestos, forming the tip of an inverted pyramid upon which the rest of the cases depend. -
CALA: Innovator liability litigation could have stifled development of new drugs
CHARLESTON – The state Supreme Court’s ruling that a consumer can’t bring a claim against a brand-name drug manufacturer when they took a generic version is drawing reaction from both sides of the issue.